» Articles » PMID: 37278339

Can Repeated Intranasal Oxytocin Administration Affect Reduced Neural Sensitivity Towards Expressive Faces in Autism? A Randomized Controlled Trial

Overview
Specialties Psychiatry
Psychology
Date 2023 Jun 6
PMID 37278339
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by difficulties in social communication and interaction. Crucial for efficient social interaction is the ability to quickly and accurately extract information from a person's face. Frequency-tagging electroencephalography (EEG) is a novel tool to quantify face-processing sensitivity in a robust and implicit manner. In terms of intervention approaches, intranasal administration of oxytocin (OT) is increasingly considered as a potential pharmacological approach for improving socio-communicative difficulties in ASD, through enhancing social salience and/or reducing (social) stress and anxiety.

Methods: In this randomized, double-blind, placebo-controlled, mechanistic pharmaco-neuroimaging clinical trial, we implemented frequency-tagging EEG to conduct an exploratory investigation into the impact of repeated OT administration (4 weeks, 12 IU, twice daily) on neural sensitivity towards happy and fearful facial expressions in children with ASD (8-12 years old; OT: n = 29; placebo: n = 32). Neural effects were assessed at baseline, post-nasal spray (24 hr after the last nasal spray) and at a follow-up session, 4 weeks after the OT administration period. At baseline, neural assessments of children with ASD were compared with those of an age- and gender-matched cohort of neurotypical (NT) children (n = 39).

Results: Children with ASD demonstrated reduced neural sensitivity towards expressive faces, as compared to NT children. Upon nasal spray administration, children with ASD displayed a significant increase in neural sensitivity at the post- and follow-up sessions, but only in the placebo group, likely reflecting an implicit learning effect. Strikingly, in the OT group, neural sensitivity remained unaffected from the baseline to the post-session, likely reflecting a dampening of an otherwise typically occurring implicit learning effect.

Conclusions: First, we validated the robustness of the frequency-tagging EEG approach to assess reduced neural sensitivity towards expressive faces in children with ASD. Furthermore, in contrast to social salience effects observed after single-dose administrations, repeated OT administration dampened typically occurring learning effects in neural sensitivity. In line with OT's social anxiolytic account, these observations possibly reflect a predominant (social) stress regulatory effect towards emotionally evocative faces after repeated OT administration.

Citing Articles

Impact of chronic intranasal oxytocin administration on face expression processing in autistic children: a randomized controlled trial using fMRI.

Moerkerke M, Daniels N, Van der Donck S, Tang T, Prinsen J, Yargholi E Mol Autism. 2024; 15(1):53.

PMID: 39709442 PMC: 11662540. DOI: 10.1186/s13229-024-00635-z.


Between faces: childhood adversity is associated with reduced threat-safety discrimination during facial expression processing in adolescence.

Samaey C, Van der Donck S, Lecei A, Vettori S, Qiao Z, van Winkel R BMC Med. 2024; 22(1):382.

PMID: 39256825 PMC: 11389258. DOI: 10.1186/s12916-024-03610-w.


Oral microbiota in autistic children: Diagnosis-related differences and associations with clinical characteristics.

Evenepoel M, Daniels N, Moerkerke M, Van de Vliet M, Prinsen J, Tuerlinckx E Brain Behav Immun Health. 2024; 38:100801.

PMID: 38882715 PMC: 11180306. DOI: 10.1016/j.bbih.2024.100801.


Chronic oxytocin administration stimulates the oxytocinergic system in children with autism.

Moerkerke M, Daniels N, Tibermont L, Tang T, Evenepoel M, Van der Donck S Nat Commun. 2024; 15(1):58.

PMID: 38167302 PMC: 10762037. DOI: 10.1038/s41467-023-44334-4.


Anti-ableism and scientific accuracy in autism research: a false dichotomy.

Bottema-Beutel K, Kapp S, Sasson N, Gernsbacher M, Natri H, Botha M Front Psychiatry. 2023; 14:1244451.

PMID: 37743979 PMC: 10514488. DOI: 10.3389/fpsyt.2023.1244451.